Valneva ( (VALN) ) has provided an announcement.
On April 26, 2025, Valneva announced that the Haute Autorité de Santé in France updated its recommendation for the use of Valneva’s chikungunya vaccine, IXCHIQ®, due to serious adverse events reported among elderly individuals with comorbidities during a vaccination campaign in La Reunion. The French health authorities have suspended the vaccine’s use in people aged 65 and older pending further investigation, although it remains recommended for those aged 18 to 64. Valneva is collaborating with regulators to determine the next steps and continues to emphasize safety and the importance of assessing vaccination benefits and risks based on individual medical histories.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s stock score reflects a company with improving financial metrics but still facing profitability hurdles. The technical analysis indicates some positive long-term momentum, but valuation concerns persist due to negative earnings. The earnings call provides a balanced outlook with both optimistic guidance and notable challenges. These factors combined suggest moderate potential, but with significant risks.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from R&D to approvals. Valneva currently markets three proprietary travel vaccines and is working on vaccine candidates for Lyme disease, Shigella, Zika virus, and other global health threats.
YTD Price Performance: 48.94%
Average Trading Volume: 81,129
Technical Sentiment Signal: Sell
Current Market Cap: $598.4M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.